Center for Drug Delivery Research, Vaccine Nanotechnology Laboratory, Mercer University, College of Pharmacy, Atlanta, GA, USA.
Center for Drug Delivery Research, Vaccine Nanotechnology Laboratory, Mercer University, College of Pharmacy, Atlanta, GA, USA.
Nanomedicine. 2019 Oct;21:102049. doi: 10.1016/j.nano.2019.102049. Epub 2019 Jul 3.
Immunocontraceptive vaccination is becoming an acceptable strategy in managing animal populations. Mass vaccination of dogs is the most cost-effective and efficient method to control rabies, and combination of rabies vaccination and animal population control will be an added advantage. In this study, we developed an adjuvanted hydrogel-based pDNA nanoparticulate vaccine for rabies protection and immunocontraception. In vivo, we observed an immune response skewed toward a Th2 type, in contrast to the Th1 type in our previous pDNA study. The observation was verified by the IgG2a/IgG1 ratio (<1), and cytokine expression profile of IL-4 and IFN-γ. The humoral immune response is key for rabies protection and a GnRH antibody-based immunocontraception. In mice, anti-GnRH antibody titers were detected 4 weeks after immunization and lasted for 12 weeks, post animal experiment was terminated. The adjuvanted pDNA nanoparticulate vaccine shows promise for future studies evaluating protection from rabies challenge and prevention of animal breeding.
免疫避孕疫苗在动物种群管理中正成为一种可接受的策略。对犬进行大规模疫苗接种是控制狂犬病最具成本效益和效率的方法，狂犬病疫苗接种与动物种群控制相结合将是一个额外的优势。在这项研究中，我们开发了一种基于水凝胶的佐剂 pDNA 纳米颗粒疫苗，用于狂犬病保护和免疫避孕。在体内，我们观察到免疫反应偏向 Th2 型，与我们之前的 pDNA 研究中的 Th1 型相反。这一观察结果通过 IgG2a/IgG1 比值（<1）和 IL-4 和 IFN-γ的细胞因子表达谱得到了验证。体液免疫反应是狂犬病保护和 GnRH 抗体免疫避孕的关键。在小鼠中，在免疫后 4 周检测到抗 GnRH 抗体滴度，并持续 12 周，在动物实验结束后。该佐剂 pDNA 纳米颗粒疫苗有望在未来的研究中评估对狂犬病挑战的保护作用和预防动物繁殖。
